A systematic review of pharmacoeconomic evaluations on oral diarylquinoline-based treatment for drug-resistant tuberculosis: from high to low burden countries

References

• Global tuberculosis report 2020. Geneva: World Health Organization; 2020. cited 2020 Oct 29. https://www.who.int/teams/global-tuberculosis-programme/tb-reports
   Google Scholar
• Dheda K, Cox H, Esmail A, et al. Recent controversies about MDR and XDR‐TB: global implementation of the WHO shorter MDR‐TB regimen and bedaquiline for all with MDR‐TB? Respirology. 2018;23(1):36–45.
   PubMed Web of Science ®Google Scholar
• Brigden G, Hewison C, Varaine F. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infect Drug Resist. 2015;8:367–378.
   PubMed Web of Science ®Google Scholar
• Dheda K, Chang K, Guglielmetti L, et al. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Microbiol Infect. 2017;23(3):131–140.
   PubMed Web of Science ®Google Scholar
• Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis–current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis. 2012;205(Suppl 2):S228–40.
   PubMed Web of Science ®Google Scholar
• Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307(5707):223–227.
   PubMed Web of Science ®Google Scholar
• Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol. 2007;3(6):323–324.
   PubMed Web of Science ®Google Scholar
• Food Drug Administration. Sirturo (bedaquiline) label. cited 2020 Sept 16 https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf
   Google Scholar
• European Medicines Agency. Sirturo (bedaquiline). 2014. cited 2020 Sept 20 https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo
   Google Scholar
• Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397–2405. .
   PubMed Web of Science ®Google Scholar
• Diacon A, Donald P, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56(6):3271–3276. .
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723–732. .
   PubMed Web of Science ®Google Scholar
• Pym AS, Diacon AH, Tang S-J, et al. Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47(2):564–574.
   PubMed Web of Science ®Google Scholar
• Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387.
   PubMed Web of Science ®Google Scholar
• WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. cited 2020 Sept 6 https://www.who.int/publications/i/item/9789240007048
   Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32(5):667–677.
   PubMed Web of Science ®Google Scholar
• Roberts M, Russell LB, Paltiel AD, et al. ISPOR-SMDM modeling good research practices task force. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Med Decis Making. 2012;32(5):678–689.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013;16(2):e1–5.
   PubMed Web of Science ®Google Scholar
• Yao J, Jiang X, You JHS. A systematic review on cost-effectiveness analyses of therapeutic drug monitoring for patients with inflammatory bowel disease: from immunosuppressive to anti-TNF Therapy. Inflamm Bowel Dis. 2021;27(2):275–282.
   PubMed Web of Science ®Google Scholar
• Sultana M, Sarker AR, Ali N, et al. Economic evaluation of community acquired pneumonia management strategies: a systematic review of literature. PLoS One. 2019;14(10):e0224170.
   PubMed Web of Science ®Google Scholar
• Wolfson LJ, Walker A, Hettle R, et al. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. PLoS One. 2015;10(3):e0120763.
   PubMed Web of Science ®Google Scholar
• Wolfson LJ, Gibbert J, Wirth D, et al. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany. Eur Respir J. 2015;46(6):1826–1829.
   PubMed Web of Science ®Google Scholar
• Wirth D, Dass R, Hettle R. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. BMC Health Serv Res. 2017;17(1):182.
   PubMedGoogle Scholar
• Schnippel K, Firnhaber C, Page-Shipp L, et al. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2018;22(8):918–925.
   PubMed Web of Science ®Google Scholar
• Schnippel K, Firnhaber C, Conradie F, et al. Incremental cost effectiveness of bedaquiline for the treatment of rifampicin-resistant tuberculosis in south africa: model-based analysis. Appl Health Econ Health Policy. 2018;16(1):43–54.
   PubMed Web of Science ®Google Scholar
• Park HY, Ku HM, Sohn HS, et al. Cost-effectiveness of Bedaquiline for the treatment of multidrug-resistant tuberculosis in the republic of Korea. Clin Ther. 2016;38(3):655–67.e1–2.
   Web of Science ®Google Scholar
• Lu X, Smare C, Kambili C, et al. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries. BMC Health Serv Res. 2017;17(1):87.
   PubMedGoogle Scholar
• Fan Q, Ming WK, Yip WY, et al. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China. Int J Infect Dis. 2019;78:44–49.
   PubMed Web of Science ®Google Scholar
• Codecasa LR, Toumi M, D’Ausilio A, et al. Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy. J Mark Access Health Policy. 2017;5(1):1283105.
   PubMedGoogle Scholar
• Mpobela Agnarson A, Williams A, Kambili C, et al. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa. Expert Rev Anti Infect Ther. 2020;18(5):475–483.
   PubMed Web of Science ®Google Scholar
• Kim DD, Wilkinson CL, Pope EF, et al. The influence of time horizon on results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):615–623.
   PubMed Web of Science ®Google Scholar
• Guglielmetti L, Jaspard M, Le Dû D, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3):1601799.
   PubMed Web of Science ®Google Scholar
• Mbuagbaw L, Guglielmetti L, Hewison C, et al. Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. Emerg Infect Dis. 2019;25(5):936–943.
   PubMed Web of Science ®Google Scholar
• Ndjeka N, Schnippel K, Master I, et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018;52(6):1801528.
   PubMed Web of Science ®Google Scholar
• Mase S, Chorba T, Parks S, et al. Bedaquiline for the treatment of multidrug-resistant tuberculosis in the United States. Clin Infect Dis. 2020;71(4):1010–1016.
   PubMed Web of Science ®Google Scholar
• Olayanju O, Limberis J, Esmail A, et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J. 2018;51(5):1800544.
   PubMed Web of Science ®Google Scholar